

Hatch Medical and Rafael Medical Technologies Sign Vena Cava Filter Agreement

Atlanta, Georgia - Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced today that it has recently entered into an agreement with Rafael Medical Technologies, Inc. (Caesarea, Israel) to broker its patented vena cava filter.

Rafael Medical's SafeFlo™, a retrievable or optional vena cava filter for the management and prevention of pulmonary embolism, utilizes shape memory alloys and proprietary design elements to create a novel intravascular structure with exceptional utility.

The use of filters implanted in the inferior vena cava is well established for the prevention of pulmonary embolism in high-risk patients, and are performed in approximately 80,000 cases each year in the United States. While current devices are sufficiently effective, most vena cava filters have limited indications since they cannot be removed, pose risks to the patient, and many are difficult and costly to implant.

Incorporating numerous product features previously unavailable, the SafeFlo™ filter offers a non-tilt, low-profile system (5 French) that allows for intraprocedure repositioning and active detachment. As a result, the SafeFlo™ filter reduces the possible risks associated with imperfect filter positioning and potentially facilitates bedside placement under ultrasound guidance. Additionally, the SafeFlo™ filter utilizes a unique fixation method that can prevent vessel damage while improving filter stability and facilitates retrieval after extended implantation periods.

"SafeFlo™ has the opportunity to expand the use of vena cava filters on a prophylactic basis among approximately two million patients that are potentially at risk of developing pulmonary embolus each year in the United States. We are very excited to be working with Rafael Medical and believe that the SafeFlo™ filter will provide innumerable benefits and greater procedural options for clinicians and patients by reducing the risks and costs associated with filter placement", commented Paul Gianneschi, President and CEO of Hatch Medical, L.L.C.

Aaron Feldman, Rafael Medical Technology's President and C.E.O. added, "We are pleased by the enthusiasm Hatch Medical has demonstrated towards our filter and the substantial benefits it affords to patients and physicians. We look forward to working with Hatch Medical to secure a partner committed to bringing this, our first, novel device to market and to realizing the full potential of prophylactic vena cava filter use."

The SafeFlo™ vena cava filter technology is available for licensing or strategic marketing relationship to interested companies through an agreement with Hatch Medical.

Hatch Medical jointly develops and brokers minimally invasive medical devices for the diagnosis and treatment of peripheral vascular, cardiovascular and oncological disease states through its network of product development experts.

SafeFlo™ is under clinical investigation and is not available for sale in any country. For additional information on this, or other Hatch Medical, L.L.C. products and services, e-mail the company at info@hatchmedical.com. This release and additional news about Hatch Medical can be obtained by visiting the company's web site at: <http://www.hatchmedical.com>.

Contact Paul Gianneschi, President and CEO, 770-982-6306, or Steve Hvozda, Executive Vice President, Business Development 404-982-9994



Hatch Medical, L.L.C.
8750 Islesworth Court
Duluth, GA 30097
Phone: 770-476-9940
Facsimile: 770-476-7740
info@hatchmedical.com

© 2001 - 2008 Hatch Medical, L.L.C. - All rights reserved